FCMI
MDGL icon

Foresite Capital Management III’s Madrigal Pharmaceuticals MDGL Stock Holding History

Foresite Capital Management III’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100,000
Closed -$4.5M – 19
2017
Q3 		$4.5M Buy
+100,000
New +$1.87M 1.24% 17

Other funds holding MDGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Foresite Capital Management III's MDGL Position: Q4 2017 in Review

Foresite Capital Management III sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2017, closing a stake of 100,000 shares — an estimated $4.5M sold.

Foresite Capital Management III first reported a position in MDGL in Q3 2017 and held it in 1 quarter. The position peaked at $4.5M in Q3 2017. 91 funds tracked by Wall St. Rank hold MDGL as of Q4 2017.

  • Foresite Capital Management III reported no remaining Madrigal Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 100,000 Madrigal Pharmaceuticals shares in Q4 2017, an estimated $4.5M.
  • Foresite Capital Management III first reported a position in Madrigal Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Foresite Capital Management III's Madrigal Pharmaceuticals position peaked at $4.5M in Q3 2017.
  • 91 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2017.

Based on Foresite Capital Management III's 13F filing for Q4 2017, filed 13 Feb 2018.